Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELUTIA INC.ELUT · Entity 7342 | Director · 10% owner | June 11, 2026 | June 15, 2026 |
| ORAMED PHARMACEUTICALS INC.ORMP · Entity 6311 | Director | March 21, 2022 | March 23, 2022 |
| Ocugen, Inc.HSGX · Entity 5550 | Director | February 08, 2019 | February 11, 2019 |
| Quantum-Si IncQSI · Entity 6440 | Director | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELUTIA INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2036-06-11 | Direct | 159,590 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 159,590 · Balance 159,590 F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continuing in service on the Issuer's board of directors through the applicable vesting date.
ORAMED PHARMACEUTICALS INC.
Report date March 21, 2022 · Filed March 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,661 |
Reported balance
After 2022-03-21 transaction · row 1
1 source rowRow 1 · 2022-03-21 · Sale · Disposed 10,000 · Balance 46,661 |
Ocugen, Inc.
Report date February 08, 2019 · Filed February 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 418,639 |
Reported balance
After 2019-02-08 transaction · row 1
1 source rowRow 1 · 2019-02-08 · Exercise / conversion · Acquired 173,076 · Balance 418,639 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 66,666 |
Reported balance
After 2019-02-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-02-08 · Exercise / conversion · Acquired 33,333 · Balance 66,666 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F2: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 66,666 |
Reported balance
After 2019-02-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-02-08 · Exercise / conversion · Acquired 33,333 · Balance 66,666 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F3: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 257,846 |
Reported balance
After 2019-02-08 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2019-02-08 · Exercise / conversion · Acquired 111,111 · Balance 257,846 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F4: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. |
| Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2023-10-10 | Direct | 0 |
Reported balance
After 2019-02-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-08 · Exercise / conversion · Disposed 173,076 · Balance 0 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. |
| Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-11-22 | IndirectSee Footnote | 0 |
Reported balance
After 2019-02-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-08 · Exercise / conversion · Disposed 33,333 · Balance 0 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F2: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein. |
| Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-11-22 | IndirectSee Footnote | 0 |
Reported balance
After 2019-02-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-02-08 · Exercise / conversion · Disposed 33,333 · Balance 0 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F3: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. |
| Common Stock Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2021-11-22 | IndirectSee Footnote | 0 |
Reported balance
After 2019-02-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-02-08 · Exercise / conversion · Disposed 111,111 · Balance 0 F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F4: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019.
F2: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein.
F3: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.
F4: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein.
Quantum-Si Inc
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.85 · Expires 2036-05-18 | Direct | 251,185 |
Reported balance
After 2026-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-18 · Grant · Acquired 251,185 · Balance 251,185 F3: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date. |
| Class A Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,200,000 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,200,000 F1: HighCape Partners QSI II Invest, L.P. distributed in kind these shares of the Company's Class A common stock to its limited partners on a pro rata basis, for no consideration. F2: Consists of (i) 24,527 shares of the Company's Class A common stock held by HighCape Partners II, L.P. and (ii) 1,175,473 shares of the Company's Class A common stock held by HighCape Partners QP II, L.P. Mr. Rakin is the managing member of HighCape Capital II GP, LLC, which is the general partner of HighCape Partners II GP, L.P., which is the general partner of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P., and as a result each may be deemed to share voting and investment discretion with respect to the Class A common stock held by such entities. |
| Class A Common StockSEC Table I · non-derivative | Direct | 20,512 |
Reported balance
Holding disclosure · report date 2026-05-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,512 |
Filing footnotes · ownership attribution and instrument terms
F1: HighCape Partners QSI II Invest, L.P. distributed in kind these shares of the Company's Class A common stock to its limited partners on a pro rata basis, for no consideration.
F2: Consists of (i) 24,527 shares of the Company's Class A common stock held by HighCape Partners II, L.P. and (ii) 1,175,473 shares of the Company's Class A common stock held by HighCape Partners QP II, L.P. Mr. Rakin is the managing member of HighCape Capital II GP, LLC, which is the general partner of HighCape Partners II GP, L.P., which is the general partner of each of HighCape Partners II, L.P. and HighCape Partners QP II, L.P., and as a result each may be deemed to share voting and investment discretion with respect to the Class A common stock held by such entities.
F3: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 09, 2021 Filed Aug 11, 2021 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 1,977 | $21.09 | $41,694.93 |
DisclosureSEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 6 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,247 F3 · shares: Represents a cashless exercise of outstanding stock options to purchase 10,000 shares of common stock. The reporting person received 8,023 shares of common stock and surrendered 1,977 shares of common stock underlying the stock option in payment of the exercise price. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 10,000 | $4.17 | $41,700.00 |
DisclosureSEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 5 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 1,517 | $21.09 | $31,993.53 |
DisclosureSEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 4 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,224 F2 · shares: Represents a cashless exercise of outstanding stock options to purchase 6,666 shares of common stock. The reporting person received 5,149 shares of common stock and surrendered 1,517 shares of common stock underlying the stock option in payment of the exercise price. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 6,666 | $4.80 | $31,996.80 |
DisclosureSEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 3 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Tax withholdingCommon Stock | 1,683 | $21.09 | $35,494.47 |
DisclosureSEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,075 F1 · shares: Represents a cashless exercise of outstanding stock options to purchase 5,697 shares of common stock. The reporting person received 4,014 shares of common stock and surrendered 1,683 shares of common stock underlying the stock option in payment of the exercise price. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:15 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Exercise / conversionCommon Stock | 5,697 | $6.23 | $35,492.31 |
DisclosureSEC source: 0001213900-21-041712 · ownership.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:27 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantClass A Common Stock | 20,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-081583 · tm2119549-25_4seq1.xml · nonDerivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,512 F4 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on June 11, 2022, subject to Mr. Rakin's continued service through the applicable vesting date. Read SEC document |
| June 10, 2021 Filed Jun 15, 2021 21:27 UTC | Quantum-Si Inc QSI · Entity 6440 | GrantClass A Common Stock | 1,901,000 | $10.00 | $19,010,000.00 |
DisclosureSEC source: 0001104659-21-081583 · tm2119549-25_4seq1.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,901,000 F1 · shares: Consists of (i) 100,000 shares of the Company's Class A common stock held by Mr. Rakin and the Kevin L. Rakin Irrevocable Trust, (ii) 601,000 shares of the Company's Class A common stock held by HighCape Partners QSI II Invest, L.P, (iii) 24,527 shares of the Company's Class A common stock held by HighCape Partners II, L.P. and F2 · shares: (iv) 1,175,473 shares of the Company's Class A common stock held by HighCape Partners QP II, L.P. Mr. Rakin and Matt Zuga are the managing members of HighCape Capital II GP, LLC, which is the general partner of HighCape Partners II GP, L.P., which is the general partner of each of HighCape Partners QSI II Invest, L.P, HighCape Partners II, L.P. and HighCape Partners QP II, L.P., and as a result each may be deemed to share voting and investment discretion with respect to the common stock held by such entities. Mr. Rakin disclaims any beneficial ownership of the securities to be held by HighCape Partners QSI II Invest, L.P, HighCape Partners II, L.P. and HighCape Partners QP II, L.P. other than to the extent of any pecuniary interest he may have therein, directly or indirectly. F3 · shares: In connection with the closing of the transactions (the "Business Combination") contemplated by the Business Combination Agreement, dated as of February 18, 2021, by and among HighCape Capital Acquisition Corp. ("HighCape"), Tenet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HighCape ("Merger Sub"), and Quantum-Si Incorporated, a Delaware corporation ("Quantum-Si"), pursuant to which Merger Sub merged with and into Quantum-Si (the "Merger"), with Quantum-Si surviving as a wholly-owned subsidiary of HighCape (which changed its name to "Quantum-Si Incorporated", the "Issuer"), these shares were purchased, at a price of $10.00 per share, in a private placement immediately prior to the closing of the Merger. F1 · ownership.nature: Consists of (i) 100,000 shares of the Company's Class A common stock held by Mr. Rakin and the Kevin L. Rakin Irrevocable Trust, (ii) 601,000 shares of the Company's Class A common stock held by HighCape Partners QSI II Invest, L.P, (iii) 24,527 shares of the Company's Class A common stock held by HighCape Partners II, L.P. and Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:44 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 14,082 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001415889-21-002895 · form4-06092021_020617.xml · derivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,082 Underlying: Class A Common Stock · 14,082 shares Expires 2031-06-06 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date. F3 · ownership.nature: Held by W. Matthew Zuga as non-employee member of the Issuer's board of directors Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 21:44 UTC | ELUTIA INC. AZYO · Entity 7342 | GrantStock Option (Right to Buy) · Derivative | 14,082 | $0.00 Strike: $10.41 | $0.00 |
DisclosureSEC source: 0001415889-21-002895 · form4-06092021_020617.xml · derivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · Director · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · Director · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,082 Underlying: Class A Common Stock · 14,082 shares Expires 2031-06-06 F1 · derivative.exercise_date: This option was granted automatically under the Issuer's Non-Employee Director Compensation Program and vests and becomes exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting following the date of grant and (ii) the first anniversary of the date of grant, subject to Messrs. Rakin's and Zuga's, as applicable, continuing in service on the Issuer's board of directors through the applicable vesting date. F2 · ownership.nature: Held by Kevin L. Rakin as non-employee member of the Issuer's board of directors Read SEC document |
| February 17, 2021 Filed Feb 17, 2021 21:21 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001213900-21-010094 · ownership.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-02-17 F1 · kind: The Stock Option will vest in 4 equal installments as follows: 3,750 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments as follows: 3,750 shall vest on each of December 31, 2021, December 31, 2022, December 31, 2023 and December 31, 2024. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | OtherWarrant · Derivative | 7,655 | $0.00 Strike: $5.44 | $0.00 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · derivative · entry 7 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 7,655 shares Expires 2027-03-01 F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | ConversionSeries A Convertible Preferred Stock · Derivative | 31,133,977 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · derivative · entry 6 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 0 Underlying: Class A Common Stock · 4,062,451 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). F6 · derivative.exercise_date: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). F6 · derivative.expiration_date: Each share of Series A preferred stock was automatically converted into 0.071659417 shares of Class A common stock upon the closing of the Issuer's initial public offering. In addition, immediately prior to the consummation of the Issuer's underwritten initial public offering of its Class A common stock, each holder of Series A preferred stockholders received, for each share of Series A preferred stock then held, 0.820876470 shares of Class A common stock (the quotient of $13.9549 divided by $17.00, the price per share of Class A common stock in such offering). F1 · ownership.nature: Consists of (i) 43,255 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,211,838 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | PurchaseClass A Common Stock | 441,176 | $17.00 | $7,499,992.00 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 4 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,508,831 F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. F5 · ownership.nature: Consists of (i) 49,118 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,652,355 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | Tax withholdingClass A Common Stock | 2,451 | $5.44 | $13,339.32 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 3 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,067,655 F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | OtherClass A Common Stock | 7,655 | $5.44 | $41,661.57 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 2 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,070,106 F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. F4 · ownership.nature: HighCape Partners QP, L.P. is the record holder of these securities. Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 01:57 UTC | ELUTIA INC. AZYO · Entity 7342 | ConversionClass A Common Stock | 4,062,451 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-114637 · a4.xml · nonDerivative · entry 1 HighCape Capital, L.P. · CIK 0001826279 · 10% owner HIGHCAPE PARTNERS, L.P. · CIK 0001598046 · 10% owner HIGHCAPE PARTNERS QP, L.P. · CIK 0001598026 · 10% owner HighCape Partners GP, LLC · CIK 0001819933 · 10% owner HighCape Partners GP, L.P. · CIK 0001819932 · 10% owner HighCape Co-Investment Vehicle I, LLC · CIK 0001819988 · 10% owner HighCape Co-Investment Vehicle II, LLC · CIK 0001820044 · 10% owner HighCape Capital, LLC · CIK 0001827500 · 10% owner Zuga Matt · CIK 0001790214 · Director · 10% owner RAKIN KEVIN · CIK 0001184421 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Footnote Disclosed balance after: 4,062,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Consists of (i) 43,255 shares of Class A common stock held by HighCape Partners, L.P.; (ii) 3,211,838 shares of Class A common stock held by HighCape Partners QP, L.P.; (iii) 499,145 shares of Class A common stock held by HighCape Co-Investment Vehicle I, LLC; (iv) 259,282 shares of Class A common stock held by HighCape Co-Investment Vehicle II, LLC and (v) 48,931 shares of Class A common stock held by HighCape Capital, L.P. F2 · ownership.nature: Kevin Rakin and W. Matthew Zuga, members of Issuer's board of directors, are the managing members of HighCape Partners GP, LLC, which in turn is the general partner of HighCape Partners GP, L.P., which in turn is the general partner of each of HighCape Partners, L.P. and HighCape Partners QP, L.P. Mr. Rakin and Mr. Zuga are the managing members of HighCape Capital, LLC, which in turn is the general partner of HighCape Capital, L.P. Each of Mr. Rakin, Mr. Zuga, HighCape Partners GP, LLC and HighCape Partners GP, L.P. may be deemed to beneficially own the securities held by HighCape Partners, L.P. and HighCape Partners QP, L.P., and each of Mr. Rakin, Mr. Zuga and HighCape Capital, LLC may be deemed to beneficially own the securities held by HighCape Capital, L.P. F3 · ownership.nature: In addition, Mr. Zuga is the managing member of each of HighCape Co-Investment Vehicle I, LLC and HighCape Co-Investment Vehicle II, LLC and may be deemed to beneficially own the securities held by such entities. Each of the reporting persons disclaims beneficial ownership of the securities held by the other reporting persons except to the extent of each reporting person's pecuniary interest therein, if any. Read SEC document |
| January 08, 2020 Filed Jan 14, 2020 21:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001213900-20-000991 · ownership.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-08 F1 · derivative.exercise_date: The Stock Option will vest in 3 installments as follows: 6,666 shall vest on December 31, 2020, and 6,667 shall vest on each of December 31, 2021 and December 31, 2022. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 22:08 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.17 | $0.00 |
DisclosureSEC source: 0001213900-19-018200 · ownership.xml · derivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-09-12 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. Read SEC document |
| April 10, 2019 Filed Apr 12, 2019 21:07 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.17 | $0.00 |
DisclosureSEC source: 0001213900-19-006288 · ownership.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-04-10 Read SEC document |
| April 10, 2019 Filed Sep 16, 2019 22:08 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.17 | $0.00 |
DisclosureSEC source: 0001213900-19-018200 · ownership.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-04-10 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:26 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative | 111,111 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000899243-19-003145 · doc4.xml · derivative · entry 8 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 111,111 shares Expires 2021-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F4 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:26 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative | 33,333 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000899243-19-003145 · doc4.xml · derivative · entry 7 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2021-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F3 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:26 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative | 33,333 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000899243-19-003145 · doc4.xml · derivative · entry 6 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 33,333 shares Expires 2021-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:26 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock Warrant (Right to Buy) · Derivative | 173,076 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000899243-19-003145 · doc4.xml · derivative · entry 5 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 173,076 shares Expires 2023-10-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:26 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock | 111,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-003145 · doc4.xml · nonDerivative · entry 4 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 257,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F4 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:26 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock | 33,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-003145 · doc4.xml · nonDerivative · entry 3 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 66,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F3 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:26 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock | 33,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-003145 · doc4.xml · nonDerivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 66,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 21:26 UTC | Ocugen, Inc. HSGX · Entity 5550 | Exercise / conversionCommon Stock | 173,076 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-003145 · doc4.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The per share exercise price of each Common Stock Warrant was re-priced to $0.01 pursuant to a warrant exercise agreement entered into with the Issuer on February 8, 2019. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 20:30 UTC | Ocugen, Inc. HSGX · Entity 5550 | PurchaseCommon Stock Warrant (Right to Buy) · Derivative | 173,076 | Not disclosed Strike: $0.70 | Not disclosed |
DisclosureSEC source: 0000899243-18-026561 · doc4.xml · derivative · entry 5 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,076 Underlying: Common Stock · 173,076 shares Expires 2023-10-10 F1 · price: The Common Stock and Common Stock Warrants were issued and sold in a fixed combination at a purchase price of $0.65 per unit. Each share of Common Stock is accompanied by a Common Stock Warrant to purchase 0.75 shares of Common Stock, which are exercisable immediately for a period of 5 years from the date of issuance. Read SEC document |
| October 10, 2018 Filed Oct 11, 2018 20:30 UTC | Ocugen, Inc. HSGX · Entity 5550 | PurchaseCommon Stock | 230,768 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-026561 · doc4.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,563 F1 · price: The Common Stock and Common Stock Warrants were issued and sold in a fixed combination at a purchase price of $0.65 per unit. Each share of Common Stock is accompanied by a Common Stock Warrant to purchase 0.75 shares of Common Stock, which are exercisable immediately for a period of 5 years from the date of issuance. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:41 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.97 | $0.00 |
DisclosureSEC source: 0000899243-18-017189 · doc4.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:43 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 56,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007162 · f4063017rakin_oramed.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,773 Underlying: Common Stock · 56,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 15,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019, and 10,000 on December 31, 2020. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 21:02 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000899243-17-016395 · doc4.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-12 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 13, 2017. Read SEC document |
| February 09, 2017 Filed Feb 16, 2017 20:45 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantStock Option (right to buy) · Derivative | 5,697 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001213900-17-001490 · f4020917rakin_oramed.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,697 Underlying: Common Stock · 5,697 shares Expires 2027-02-09 F1 · derivative.exercise_date: The Stock Option will vest immediately. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0000899243-16-035942 · doc4.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2026-12-16 F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 22, 2016. Read SEC document |
| December 06, 2016 Filed Dec 7, 2016 16:11 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 3,300 | $6.59 | $21,762.84 |
DisclosureSEC source: 0001213900-16-019206 · f4120516rakin_oramedpharma.xml · nonDerivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,061 F2 · price: This transaction was executed in multiple trades at prices ranging from $6.40 to $6.65. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 16:11 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 2,300 | $6.38 | $14,665.03 |
DisclosureSEC source: 0001213900-16-019206 · f4120516rakin_oramedpharma.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,761 F1 · price: This transaction was executed in multiple trades at prices ranging from $6.36 to $6.39. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected. Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 19:24 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 7,261 | $6.21 | $45,057.41 |
DisclosureSEC source: 0001213900-16-019147 · f4120116rakin_oramed.xml · nonDerivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,461 F2 · price: This transaction was executed in multiple trades at prices ranging from $6.07 to $6.30. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:24 UTC | ORAMED PHARMACEUTICALS INC. ORMP · Entity 6311 | GrantCommon Stock | 2,200 | $6.08 | $13,370.94 |
DisclosureSEC source: 0001213900-16-019147 · f4120116rakin_oramed.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F1 · price: This transaction was executed in multiple trades at prices ranging from $6.00 to $6.15. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | ConversionSeries A Convertible Preferred Stock · Derivative | 200.2455 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-034850 · doc4.xml · derivative · entry 6 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 88,998 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.exercise_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.expiration_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.underlying_shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F4 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | ConversionSeries A Convertible Preferred Stock · Derivative | 60.0728 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-034850 · doc4.xml · derivative · entry 5 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 26,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.exercise_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.expiration_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.underlying_shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F3 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | ConversionSeries A Convertible Preferred Stock · Derivative | 60.0728 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-034850 · doc4.xml · derivative · entry 4 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 26,699 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.exercise_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.expiration_date: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · derivative.underlying_shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | ConversionCommon Stock | 88,998 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-034850 · doc4.xml · nonDerivative · entry 3 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 228,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F4 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | ConversionCommon Stock | 26,699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-034850 · doc4.xml · nonDerivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 139,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F3 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| November 30, 2016 Filed Dec 2, 2016 22:00 UTC | Ocugen, Inc. HSGX · Entity 5550 | ConversionCommon Stock | 26,699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-034850 · doc4.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 112,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F1 · price: All outstanding shares of the Issuer's Series A Convertible Preferred Stock converted on a 1:444.444444 basis into shares of the Issuer's Common Stock. These shares have no expiration date. F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 21:15 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantCommon Stock Warrant (Right to Buy) · Derivative | 111,111 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0000899243-16-030577 · doc4.xml · derivative · entry 9 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 177,777 Underlying: Common Stock · 111,111 shares Expires not disclosed F5 · derivative.exercise_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date. F5 · derivative.expiration_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date. F3 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 21:15 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantCommon Stock Warrant (Right to Buy) · Derivative | 33,333 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0000899243-16-030577 · doc4.xml · derivative · entry 8 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 66,666 Underlying: Common Stock · 33,333 shares Expires not disclosed F5 · derivative.exercise_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date. F5 · derivative.expiration_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date. F2 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Julia Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 21:15 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantCommon Stock Warrant (Right to Buy) · Derivative | 33,333 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0000899243-16-030577 · doc4.xml · derivative · entry 7 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 33,333 Underlying: Common Stock · 33,333 shares Expires not disclosed F5 · derivative.exercise_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date. F5 · derivative.expiration_date: The Common Stock Warrants are exercisable at any time on or after the date (the "Initial Exercise Date") that the Company's stockholders approve the transactions contemplated by that certain securities purchase agreement dated September 15, 2016 pursuant to which the warrants were issued through the close of business on the five year anniversary of the Initial Exercise Date. F1 · ownership.nature: The reportable securities are owned by the Alison N Hoffman and Kevin L Rakin Irrevocable Trust For Sarah Hoffman Rakin. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 21:15 UTC | Ocugen, Inc. HSGX · Entity 5550 | GrantSeries A Convertible Preferred Stock · Derivative | 200.2455 | $1,000.00 | $200,245.50 |
DisclosureSEC source: 0000899243-16-030577 · doc4.xml · derivative · entry 6 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 320.3911 Underlying: Common Stock · 88,998 shares Expires not disclosed F4 · derivative.exercise_price: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock F4 · shares: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock F4 · derivative.exercise_date: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock F4 · derivative.expiration_date: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock F4 · derivative.underlying_shares: The shares of Series A Convertible Preferred Stock have a stated value of $1,000 per share and will be convertible into shares of the Issuer's Common Stock, subject to certain conditions including the receipt of requisite stockholder approval pursuant to the Certificate of Designation governing the rights, preferences and privileges of the Series A Convertible Preferred Stock. The initial conversion price of $2.25 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination, reclassification or other recapitalization affecting the Issuer's Common Stock F3 · ownership.nature: The reportable securities are owned by the Kevin L Rakin Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.